Carl June UPenn Research

Introduction to Carl June and UPenn Research

Carl June is a renowned American immunologist and professor of immunotherapy at the University of Pennsylvania (UPenn). He has made significant contributions to the field of cancer treatment, particularly in the development of chimeric antigen receptor (CAR) T-cell therapy. This innovative approach has shown promising results in treating various types of blood cancers, including leukemia and lymphoma. In this article, we will delve into the details of Carl June’s research at UPenn and its impact on the medical community.

Background and Education

Carl June was born in 1953 in Baltimore, Maryland. He received his Bachelor’s degree in biology and chemistry from the United States Naval Academy in 1975. He then went on to earn his medical degree from the Baylor College of Medicine in 1979. June completed his residency in internal medicine at the National Naval Medical Center in Bethesda, Maryland. He later earned his Ph.D. in immunology from the Naval Medical Research Institute in 1984.

Career and Research

Carl June began his career as a naval officer and research scientist at the Naval Medical Research Institute. He later joined the faculty at the University of Pennsylvania in 1999, where he is currently a professor of immunotherapy and the director of the Center for Cellular Immunotherapies. June’s research focuses on the development of immunotherapies for cancer treatment, including CAR T-cell therapy.

Chimeric Antigen Receptor (CAR) T-Cell Therapy

CAR T-cell therapy involves genetically modifying a patient’s T-cells to recognize and attack cancer cells. This is achieved by introducing a chimeric antigen receptor (CAR) into the T-cells, which allows them to bind to specific antigens on the surface of cancer cells. The modified T-cells are then infused back into the patient, where they can recognize and eliminate cancer cells. June’s research has led to the development of several CAR T-cell therapies, including tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta).

Impact and Recognition

Carl June’s research has had a significant impact on the field of cancer treatment. His work on CAR T-cell therapy has led to the development of life-saving treatments for patients with acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). June has received numerous awards and honors for his contributions, including the Lasker-DeBakey Clinical Medical Research Award and the National Medal of Science.

💡 Note: The success of CAR T-cell therapy has also led to the establishment of the Center for Cellular Immunotherapies at UPenn, which is dedicated to the development and translation of immunotherapies for cancer treatment.

Current Research and Future Directions

Carl June’s current research focuses on improving the efficacy and safety of CAR T-cell therapy. He is also exploring the use of immunotherapies for the treatment of solid tumors, such as breast cancer and lung cancer. June’s work has paved the way for the development of next-generation immunotherapies that have the potential to revolutionize the treatment of cancer.

Table of CAR T-Cell Therapies

Therapy	Indication	Approval Status
Tisagenlecleucel (Kymriah)	ALL, DLBCL	Approved
Axicabtagene ciloleucel (Yescarta)	DLBCL	Approved
Lisocabtagene maraleucel (Breyanzi)	DLBCL	Approved

In summary, Carl June’s research at UPenn has led to the development of innovative immunotherapies for cancer treatment, including CAR T-cell therapy. His work has had a significant impact on the medical community and has improved the lives of patients with blood cancers. As research continues to advance, it is likely that immunotherapies will play an increasingly important role in the treatment of cancer.